Companies: 10,795·Total market cap: $144.5T
Rein Therapeutics Inc.

Rein Therapeutics Inc.

RNTXNASDAQHealthcare● Active
$0.91
$-0.04(-3.88%)
Market Cap$25493053
P/E Ratio—
52W High$2.18
52W Low$0.915
SEC Filings

Rein Therapeutics Inc. (RNTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001420565 · RNTX · NASDAQ · as of Jun 9, 2026

Filing snapshot

517
Total Filings
ARS
Latest Form
2026-06-08
Most Recent
2017
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001420565 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-27
Fiscal Year End
Apr 27, 2026
Accession No.
0001193125-26-178787
Primary Document
rntx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001420565 · Accession 0001193125-26-178787

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-04Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
ARSARS
ARS
2026-06-08
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-06-08
View
DEF 14AProxy Statement
DEF 14A
2026-06-08
View
PRE 14APRE 14A
PRE 14A
2026-05-28
View
10-QQuarterly Report
10-Q
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-08
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-08
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-07
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-06
View
8-KCurrent Report
8-K
2026-05-04
View
424B5424B5
424B5
2026-05-04
View
EFFECTEFFECT
EFFECT
2026-04-30
View
CORRESPCORRESP
CORRESP
2026-04-28
View
CORRESPCORRESP
CORRESP
2026-04-28
View
S-1IPO Registration Statement
S-1
2026-04-28
View
Showing 1–15 of 352 filingsForm 4 / 144 hidden· 517 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001420565  |  Exchange: NASDAQ · Healthcare

Rein Therapeutics Inc. (NASDAQ: RNTX) has submitted 517 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001420565, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Rein Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Rein Therapeutics Inc. 10-K was filed on 2026-04-27 for fiscal year ending 2026. Historical RNTX 10-K annual reports are available from 2007 through 2026.

Investors researching Rein Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
MRSN SEC Filings →KZR SEC Filings →YI SEC Filings →ATNM SEC Filings →BEAT SEC Filings →CELU SEC Filings →QNTM SEC Filings →TPST SEC Filings →
→ RNTX Financials→ RNTX Earnings→ RNTX Insider Trades

Frequently Asked Questions

RNTX SEC Filings · 8 questions

Rein Therapeutics Inc. (RNTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 517 filings and access original documents at no cost. Rein Therapeutics Inc.'s CIK is 0001420565.

RNTX SEC filingsRein Therapeutics Inc. SEC documentsfind RNTX 10-K